RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets.
Trends Pharmacol Sci
; 42(4): 268-282, 2021 04.
Article
in En
| MEDLINE
| ID: mdl-33711255
ABSTRACT
Cancer transcriptomes frequently exhibit RNA dysregulation. As the resulting aberrant transcripts may be translated into cancer-specific proteins, there is growing interest in exploiting RNA dysregulation as a source of tumor antigens (TAs) and thus novel immunotherapy targets. Recent advances in high-throughput technologies and rapid accumulation of multiomic cancer profiling data in public repositories have provided opportunities to systematically characterize RNA dysregulation in cancer and identify antigen targets for immunotherapy. However, given the complexity of cancer transcriptomes and proteomes, important conceptual and technological challenges exist. Here, we highlight the expanding repertoire of TAs arising from RNA dysregulation and introduce multiomic and big data strategies for identifying optimal immunotherapy targets. We discuss extant barriers for translating these targets into effective therapies as well as the implications for future research.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
RNA
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Trends Pharmacol Sci
Year:
2021
Document type:
Article
Affiliation country:
United States